Phase II safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive follicular lymphoma. A phase I study of ...

Major proposed mechanisms of immune evasion by lymphoma cells and the related molecules involved in each mechanism: “Hide” (MHC-I, MHC-II, CD58, CD54, CD80, CD86), “Defend” (CD95/FAS, BCL-2), ...

Traits of noncancerous cells in diffuse large B-cell lymphoma (DLBCL) tumors appear to offer insight into which patients will benefit the most from chimeric antigen receptor (CAR) T-cell therapy, ...

Overexpression of MYC and BCL2 in DLBCL is linked to increased CCL2 and CCR2, promoting M2 macrophage polarization and aggressiveness. Elevated CCL2 and CCR2 expression correlates with poor ...

Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL) Immune-privileged DLBCLs contain many T cells mixed with tumor B cells and show signs that ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...

In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...

—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...

Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which ...

NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific ...